ATM and breast carcinoma: Overall, these results demonstrated that encapsulation of ATA in the NPs did not decrease its anticancer efficacy compared with free ATA on ER+ breast cancer MCF-7 cells; thus, the ATA NPs formulation successfully retained the original anticancer efficacy of ATA.